You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome
SBC: Pharmareview Corporation Topic: NIGMSDESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lactoferrin that contains humanized glycosylation patterns. SIRS is a clinical expression of the action of complex acute-phase intrinsic mediators that precedes sepsis and subsequent tissue damage leadin ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Learning System for Continuous Professional Education in Low Vision Rehabilitatio
SBC: Emerald Events, Inc. Topic: NEIEmerald Education Systems has developed an online continuing professional education learning system that targets low vision rehabilitation service providers. This CE learning system has three components: 1) a set of coordinated in depth online courses that provide a broad and deep foundation of knowledge on low vision rehabilitation that is delivered using a didactic approach at a learner-controll ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral gene therapy for mucopolysaccharidosis
SBC: LENTIGEN CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral-MGMT gene transfer into hematopoietic stem cells
SBC: LENTIGEN CORPORATION Topic: NCIDESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Low-Cost, Noninvasive Liver Iron Measurements in African American Iron Overload
SBC: Avrin, William F. Topic: NIMHDDESCRIPTION (provided by applicant): This STTR program will test the utility of a low-cost device for noninvasive liver iron measurements, by using the device to determine the prevalence of iron overload in African Americans. African American iron overload is both an under-studied health issue in a medically underserved population, and an example of the wider problem of mild to moderate iron overl ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
LystaMab Immunotherapy to Inhibit Pericardial Adhesions
SBC: LYST THERAPEUTICS LLC Topic: NHLBISUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Making Standing Balance The Fifth Vital Sign in Clinical Settings
SBC: Bertec Corporation Topic: NIAFalls are a significant source of early morbidity and mortality in the aging population, yet the neurological,sensory, and motor changes that lead to increased fall risk often escape early identification and intervention. Vital signs are commonly used in clinical settings to assess the cardiovascular system (blood pressure, heart rate), immune system (body temperature), and the respiratory system ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Me & You-Tech: A socio-ecological solution to teen dating violence for the digital age.
SBC: Radiant Creative Group, LLC Topic: NICHDABSTRACT The goal of thisyear Fast Track STTR is to develop and evaluate a multi levelyouthparentschoolInternet based dating violenceDVprevention programMe andampYou TechMYTforthgrade middle school studentsByth gradeapproximatelyof students will have engaged in a dating relationshipOf thesealmost one third will have perpetrated physical DV and almost two thirds will have perpetrated emotional DVYo ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Measuring and monitoring carbon nanotubes and their potential toxicity
SBC: Medical Nanotechnologies, Inc. Topic: NIEHSDESCRIPTION (provided by applicant): The Environmental Protection Agency (EPA) recently classified carbon nanotubes (CNTs) as a new chemical substance. Consequently, CNTs are now subject to regulatory controls that require inventory control, quantification of CNT amounts, and possibly toxicity tests. However, rapidly and inexpensively quantifying the CNTs in commercially available material and ass ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Dysfunction in HAART: Point of Care Tests
SBC: MITOSCIENCES, INC Topic: NIGMSDESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health